Does unified allergic airway disease impact on lung function and type 2 biomarkers?

Chris Ruiwen Kuo, Rory Chan, Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journalLetter

15 Downloads (Pure)

Abstract

The concept of the unified allergic airway disease (UAD) recognises the association between allergic inflammation in the upper and lower airways. Patients with asthma and concomitant allergic rhinitis experience more asthma-related primary and secondary care visits. We therefore aimed to determine differences in asthma control (asthma control questionnaire ACQ-6), lung function (spirometry) and T2 biomarkers (FeNO and Eos) in relation to the presence of allergic rhinitis in patients with allergic asthma. Retrospectively, we evaluated a cohort of 60 consecutive patients with persistent asthma attending our research unit for screening into clinical trials. All included subjects were receiving inhaled corticosteroids (ICS) and had a positive skin prick test (SPT) to at least one common aeroallergen to fulfil the criterion of allergic asthma. Patients with UAD had a diagnosis of allergic asthma in addition to established concomitant allergic rhinitis. T2 biomarkers were significantly higher in patients with allergic rhinitis in contrast to those without. FEV1 % predicted and FEF25-75 % predicted were also significantly lower in patients with concomitant allergic rhinitis. However, there was no difference in ACQ-6 observed between groups. In summary, patients with allergic asthma, the presence of concomitant allergic rhinitis is associated with worse lung function and higher type 2 biomarkers.
Original languageEnglish
Article number75
Pages (from-to)1-4
Number of pages4
JournalAllergy, Asthma & Clinical Immunology
Volume15
Issue number1
DOIs
Publication statusPublished - 27 Nov 2019

Fingerprint

Asthma
Biomarkers
Lung
Secondary Care
Spirometry
Skin Tests
Allergic Rhinitis
Primary Health Care
Adrenal Cortex Hormones
Clinical Trials
Inflammation
Research

Keywords

  • Allergic rhinitis
  • Asthma
  • Asthma control questionnaire
  • Eosinophil
  • Fractional exhaled nitric oxide
  • Spirometry
  • Unified allergic airway disease

Cite this

@article{3f4bf1e22ae644cd80e4a69aa49c5727,
title = "Does unified allergic airway disease impact on lung function and type 2 biomarkers?",
abstract = "The concept of the unified allergic airway disease (UAD) recognises the association between allergic inflammation in the upper and lower airways. Patients with asthma and concomitant allergic rhinitis experience more asthma-related primary and secondary care visits. We therefore aimed to determine differences in asthma control (asthma control questionnaire ACQ-6), lung function (spirometry) and T2 biomarkers (FeNO and Eos) in relation to the presence of allergic rhinitis in patients with allergic asthma. Retrospectively, we evaluated a cohort of 60 consecutive patients with persistent asthma attending our research unit for screening into clinical trials. All included subjects were receiving inhaled corticosteroids (ICS) and had a positive skin prick test (SPT) to at least one common aeroallergen to fulfil the criterion of allergic asthma. Patients with UAD had a diagnosis of allergic asthma in addition to established concomitant allergic rhinitis. T2 biomarkers were significantly higher in patients with allergic rhinitis in contrast to those without. FEV1 {\%} predicted and FEF25-75 {\%} predicted were also significantly lower in patients with concomitant allergic rhinitis. However, there was no difference in ACQ-6 observed between groups. In summary, patients with allergic asthma, the presence of concomitant allergic rhinitis is associated with worse lung function and higher type 2 biomarkers.",
keywords = "Allergic rhinitis, Asthma, Asthma control questionnaire, Eosinophil, Fractional exhaled nitric oxide, Spirometry, Unified allergic airway disease",
author = "Kuo, {Chris Ruiwen} and Rory Chan and Brian Lipworth",
note = "{\circledC} The Author(s) 2019.",
year = "2019",
month = "11",
day = "27",
doi = "10.1186/s13223-019-0388-4",
language = "English",
volume = "15",
pages = "1--4",
number = "1",

}

Does unified allergic airway disease impact on lung function and type 2 biomarkers? / Kuo, Chris Ruiwen; Chan, Rory; Lipworth, Brian (Lead / Corresponding author).

In: Allergy, Asthma & Clinical Immunology, Vol. 15, No. 1, 75, 27.11.2019, p. 1-4.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Does unified allergic airway disease impact on lung function and type 2 biomarkers?

AU - Kuo, Chris Ruiwen

AU - Chan, Rory

AU - Lipworth, Brian

N1 - © The Author(s) 2019.

PY - 2019/11/27

Y1 - 2019/11/27

N2 - The concept of the unified allergic airway disease (UAD) recognises the association between allergic inflammation in the upper and lower airways. Patients with asthma and concomitant allergic rhinitis experience more asthma-related primary and secondary care visits. We therefore aimed to determine differences in asthma control (asthma control questionnaire ACQ-6), lung function (spirometry) and T2 biomarkers (FeNO and Eos) in relation to the presence of allergic rhinitis in patients with allergic asthma. Retrospectively, we evaluated a cohort of 60 consecutive patients with persistent asthma attending our research unit for screening into clinical trials. All included subjects were receiving inhaled corticosteroids (ICS) and had a positive skin prick test (SPT) to at least one common aeroallergen to fulfil the criterion of allergic asthma. Patients with UAD had a diagnosis of allergic asthma in addition to established concomitant allergic rhinitis. T2 biomarkers were significantly higher in patients with allergic rhinitis in contrast to those without. FEV1 % predicted and FEF25-75 % predicted were also significantly lower in patients with concomitant allergic rhinitis. However, there was no difference in ACQ-6 observed between groups. In summary, patients with allergic asthma, the presence of concomitant allergic rhinitis is associated with worse lung function and higher type 2 biomarkers.

AB - The concept of the unified allergic airway disease (UAD) recognises the association between allergic inflammation in the upper and lower airways. Patients with asthma and concomitant allergic rhinitis experience more asthma-related primary and secondary care visits. We therefore aimed to determine differences in asthma control (asthma control questionnaire ACQ-6), lung function (spirometry) and T2 biomarkers (FeNO and Eos) in relation to the presence of allergic rhinitis in patients with allergic asthma. Retrospectively, we evaluated a cohort of 60 consecutive patients with persistent asthma attending our research unit for screening into clinical trials. All included subjects were receiving inhaled corticosteroids (ICS) and had a positive skin prick test (SPT) to at least one common aeroallergen to fulfil the criterion of allergic asthma. Patients with UAD had a diagnosis of allergic asthma in addition to established concomitant allergic rhinitis. T2 biomarkers were significantly higher in patients with allergic rhinitis in contrast to those without. FEV1 % predicted and FEF25-75 % predicted were also significantly lower in patients with concomitant allergic rhinitis. However, there was no difference in ACQ-6 observed between groups. In summary, patients with allergic asthma, the presence of concomitant allergic rhinitis is associated with worse lung function and higher type 2 biomarkers.

KW - Allergic rhinitis

KW - Asthma

KW - Asthma control questionnaire

KW - Eosinophil

KW - Fractional exhaled nitric oxide

KW - Spirometry

KW - Unified allergic airway disease

UR - http://www.scopus.com/inward/record.url?scp=85075831367&partnerID=8YFLogxK

U2 - 10.1186/s13223-019-0388-4

DO - 10.1186/s13223-019-0388-4

M3 - Letter

C2 - 31788008

VL - 15

SP - 1

EP - 4

IS - 1

M1 - 75

ER -